Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis
NCT02633371Completed
- Sponsor
- University of Colorado Denver
- Start
- Feb 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of oxybutynin in primary focal hyperhidrosis (PFH), sponsored by University of Colorado Denver. Primary endpoint: Number of Patients With Improvement in Hyperhidrosis Severity as Measured by the Hyperhidrosis Disease Severity Scale at 4 weeks. Started Feb 2016; status: completed.
02
Drugs
oxybutynin
03
Conditions
primary focal hyperhidrosis (PFH)
Beyond the preview
Go deeper on NCT02633371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633371.